Table 1. Correlation of relative lncRNA XIST expression with the clinicopathological characteristics of patients with prostate cancer.
| LncRNA XIST expression* | |||||
|---|---|---|---|---|---|
| Parameters | Group | High | Low | Total | P value |
| Age | <70 | 18 | 9 | 27 | 0.324 |
| ≥70 | 19 | 16 | 35 | ||
| Metastasis | Absence | 26 | 7 | 33 | <0.01 |
| Presence | 11 | 18 | 29 | ||
| Clinical stage | T1 | 20 | 5 | 25 | 0.012 |
| T2/T3 | 18 | 19 | 37 | ||
| Preoperative PSA | <4 | 14 | 4 | 18 | 0.044 |
| 4-10 | 6 | 7 | 13 | ||
| >10 | 13 | 18 | 31 | ||
| Gleason score | <7 | 17 | 5 | 22 | 0.019 |
| 7 | 4 | 6 | 10 | ||
| >7 | 12 | 18 | 30 | ||
*The mean (2.2) of the relative expression of lncRNA XIST in tumor tissues of all paired samples was used as a cut-off to classify a tumor sample was high or low according to their XIST expression levels.